Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Masitinib is dosed at 12.5 mg/kg PO q24h in dogs, per Hahn KA, Oglivie G, Rusk T et al. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumours. Journal of Veterinary Internal Medicine 22, 1301-1309 doi:10.1111/j.1939-1676.2008.0190.x — Verified against BSAVA Small Animal Formulary, 10th Ed, Part A, p.262 (2026-08-01). — LOCATOR CONVENTION 2026-08-07: the bare 'p.262' in this citation is the PDF index of the held scan, not the printed page. The PRINTED page is p.246; verified by finding the drug named there. If you are holding the book, turn to p.246. — SOURCE EDITION: BSAVA Small Animal Formulary, Part A — Canine and Feline — ISBN 9781910443705, https://openlibrary.org/isbn/9781910443705. Masitinib is used in dogs for Non-resectable mast cell tumors. Routes documented in dogs: PO. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Masitinib in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Masivet, Kinavet
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| PO | 12.5 mg/kg | q24h | Long-term | Non-resectable mast cell tumors | Moderate | Hahn KA, Oglivie G, Rusk T et al. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumours. Journal of Veterinary Internal Medicine 22, 1301-1309 doi:10.1111/j.1939-1676.2008.0190.x — Verified against BSAVA Small Animal Formulary, 10th Ed, Part A, p.262 (2026-08-01). — LOCATOR CONVENTION 2026-08-07: the bare 'p.262' in this citation is the PDF index of the held scan, not the printed page. The PRINTED page is p.246; verified by finding the drug named there. If you are holding the book, turn to p.246. — SOURCE EDITION: BSAVA Small Animal Formulary, Part A — Canine and Feline — ISBN 9781910443705, https://openlibrary.org/isbn/9781910443705 |
Every held source for this drug and species, as printed. Where they differ, both are shown — the choice is yours, not ours.
| Dose (mg/kg) | Route | Source | As printed |
|---|---|---|---|
| 11–14 | PO | BSAVA Small Animal Formulary, 10th ed — Part A (Canine and Feline)p.262 | 11-14 mg/kg p.o. q24h (usually 12.5 mg/kg p.o. q24h) |
| 12.5 | PO | BSAVA Small Animal Formulary, 10th ed — Part A (Canine and Feline)p.262 | 11-14 mg/kg p.o. q24h (usually 12.5 mg/kg p.o. q24h) |
Figures are transcribed from the cited page or table of each held edition and are shown for reference only. They are not dose recommendations, they do not feed the calculator, and none has been reviewed by a veterinarian.
Need the exact dose for your patient?
These ranges are per kg. Enter your dog's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Selectively inhibits c-Kit receptor tyrosine kinase, PDGFR, and Lyn kinase. Targets mast cell tumor growth signaling. Also inhibits FGFR3.
Approved for non-resectable grade II/III mast cell tumors with confirmed c-Kit mutation. GI upset, neutropenia, protein-losing nephropathy. Monitor CBC and urinalysis.
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Masitinib dose range in dogs, with cited source references: PO 12.5 mg/kg q24h. Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Masitinib in dogs: PO.
Cited course lengths for Masitinib in dogs include: Long-term. Duration depends on the indication — match it to the specific dose rule in the table above.
Masitinib is indicated in dogs for: Non-resectable mast cell tumors.
These are general warnings for Masitinib across species; consult the dog dosing table above for species-specific guidance. Approved for non-resectable grade II/III mast cell tumors with confirmed c-Kit mutation. GI upset, neutropenia, protein-losing nephropathy. Monitor CBC and urinalysis.
Why a species-specific page? Masitinib pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.